Analog Devices announced U.S. FDA 510(k) clearance and the commercial launch of the Sensinel Cardiopulmonary Management System. The compact wearable device is a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure. It is the first FDA clearance the company has received in its 59-year history. ADI‘s Sensinel CPM System is now commercially available.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADI:
- Analog Devices price target lowered to $222 from $226 at Truist
- Analog Devices price target lowered to $212 from $219 at Morgan Stanley
- UBS semiconductors analyst to hold an analyst/industry conference call
- Analog Devices expands partnership with TSMC
- Analog Devices price target raised to $220 from $210 at Citi
